Skip to main content
大禹生物 logo

大禹生物 — Investor Relations & Filings

Ticker · 920970 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 384 across all filing types
Latest filing 2024-08-27 Capital/Financing Update
Country CN China
Listing Beijing Stock Exchange 920970

About 大禹生物

http://www.sxdysw.cn/

Shanxi Dayu Biological Assistance Co., Ltd. specializes in the research, development, and production of advanced animal nutrition and health solutions. The company focuses on the manufacturing of feed additives, micro-ecological preparations, and biological feed products. Its core portfolio includes probiotics, enzyme preparations, and functional premixes designed to enhance livestock immunity, improve feed conversion rates, and promote sustainable farming practices. By leveraging biotechnology, the firm provides integrated solutions for the aquaculture and animal husbandry sectors, emphasizing scientific innovation and product quality to support the modernization of the agricultural supply chain.

Recent filings

Filing Released Lang Actions
募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "募集资金存放与实际使用情况的专项报告" which translates to a "Special Report on the Deposit and Actual Use of Raised Funds." It details the issuance of shares, the amount of funds raised, their usage, and the management of these funds. It includes specific financial figures related to the raised capital, usage progress, and compliance with regulatory requirements. The document is focused on the use and management of capital raised through a public offering, which aligns with updates on company fundraising and capital structure changes. The document length is 3555 characters, which is relatively short but contains substantive financial data about capital usage rather than just an announcement or a certification. Therefore, it is not a report publication announcement or a regulatory filing. The content fits best under the category of Capital/Financing Update (CAP), as it provides detailed information on the raised funds and their deployment.
2024-08-27 Chinese
2024年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as a "半年度报告" which translates to "Half-Year Report" or "Interim Report" for the period January 1, 2024 to June 30, 2024. It contains detailed financial data including income statement, balance sheet, cash flow analysis, segment revenue, and operational commentary. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement. It explicitly states it is a half-year report and includes comprehensive financial and operational information, which matches the definition of an Interim / Quarterly Report (IR). There is no indication that this is an announcement of a report or a certification letter, so it is not RPA or RNS. Therefore, the document is classified as an Interim / Quarterly Report (IR). H1 2024
2024-08-27 Chinese
国投证券股份有限公司关于山西大禹生物工程股份有限公司部分募投项目用途变更的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed verification opinion from the sponsoring institution (国投证券股份有限公司) regarding the change in use of certain raised funds by 山西大禹生物工程股份有限公司. It includes specifics about the fundraising amount, usage progress, storage of funds, reasons for the change in project use, industry analysis, and the impact on the company. It also mentions that the change has been approved by the board and supervisory committee and will be submitted to the shareholders' meeting. The document is 4293 characters long, which is relatively short but contains substantive content about the use of raised capital and related approvals. It is not a full annual or interim report, nor is it a simple announcement or certification. The content focuses on the use of capital raised from a public offering and the change in the use of those funds, which aligns with a Capital/Financing Update filing. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2024-08-27 Chinese
关于召开2024年第二次临时股东大会通知公告（提供网络投票）
Regulatory Filings Classification · 95% confidence The document is a notice announcing the convening of the 2024 second extraordinary general meeting of shareholders (临时股东大会) for Shanxi Dayu Bioengineering Co., Ltd. It details the meeting date, voting methods (onsite and online), eligibility, agenda items, registration procedures, and contact information. It does not contain any financial statements, audit results, or detailed financial data. The document is primarily an announcement about the meeting itself, not the results or materials of the meeting. It also references a previous announcement about a project usage change but does not include substantive report content. The document length is about 2059 characters, which is relatively short and consistent with a meeting notice. Therefore, this document fits best into the category of a Regulatory Filing (RNS) as a general regulatory announcement about a shareholder meeting, rather than a full report or voting results announcement.
2024-08-27 Chinese
第三届监事会第十二次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Shanxi Dayu Bioengineering Co., Ltd. It details the meeting date, attendance, and voting results on several agenda items, including approval of the 2024 semi-annual report and related disclosures. However, the actual semi-annual report and other detailed reports are referenced as being published separately on the Beijing Stock Exchange information disclosure platform with specific announcement numbers. The document itself is short (1331 characters) and serves as a formal announcement of meeting resolutions rather than containing the full financial report or substantive financial data. Therefore, it fits the category of a Regulatory Filing (RNS) as a formal announcement of meeting resolutions and references to other filings, rather than the report itself or a detailed financial report.
2024-08-27 Chinese
股票解除限售公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement regarding the lifting of stock sale restrictions (解除限售公告) for a specific company, detailing the number of shares becoming tradable, the shareholders involved, and the reasons for lifting the restrictions. It includes tables with shareholding details and explanations about the nature of the shares and compliance with stock exchange rules. There is no financial performance data, earnings information, or management discussion. The document is regulatory in nature, related to share capital and shareholder information but does not announce new share issuance or capital changes per se. It is not a full financial report or earnings release. Given the content and length (2111 characters), it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-06-06 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.